MX355198B - Nuevas composiciones y procesos para preparar formulaciones de 1,2,3-triazoles 5-amino o amino sustituidos y triazol orotato. - Google Patents
Nuevas composiciones y procesos para preparar formulaciones de 1,2,3-triazoles 5-amino o amino sustituidos y triazol orotato.Info
- Publication number
- MX355198B MX355198B MX2014012090A MX2014012090A MX355198B MX 355198 B MX355198 B MX 355198B MX 2014012090 A MX2014012090 A MX 2014012090A MX 2014012090 A MX2014012090 A MX 2014012090A MX 355198 B MX355198 B MX 355198B
- Authority
- MX
- Mexico
- Prior art keywords
- amino
- processes
- triazoles
- formulations
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a nuevos polimorfos de 1,2,3-triazol 5-amino o amino sustituido y derivados sustitutos de los mismos, de orotatos de carboxiamidotriazoles, de formulaciones de los triazoles y ácido orótico en la proporción de 1:1 a 1:4 (base:ácido) y de procesos más seguros para la preparación de los mismos. Los compuestos son útiles en el control y el tratamiento de enfermedades que incluyen, pero no se limitan a cánceres sólidos, degeneración macular, retinopatía, leucemia mielógena crónica, SIDA, y enfermedades que dependen de la transducción aberrante de señal. Los procesos mejorados para preparar las formulaciones de orotato utilizan materiales de inicio de intermediarios azida, estables, eficientes y más seguros en la síntesis de nuevos polimorfos de carboxiamidotriazol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58444809A | 2009-09-04 | 2009-09-04 | |
| US12/807,415 US8377973B2 (en) | 2009-09-04 | 2010-09-03 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX355198B true MX355198B (es) | 2018-04-06 |
Family
ID=43648255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002730A MX2012002730A (es) | 2009-09-04 | 2010-09-03 | Nuevas composiciones y procesos para preparar formulaciones de 1,2,3-triazoles 5-amino o amino sustituidos y triazol orotato. |
| MX2014012090A MX355198B (es) | 2009-09-04 | 2012-03-02 | Nuevas composiciones y procesos para preparar formulaciones de 1,2,3-triazoles 5-amino o amino sustituidos y triazol orotato. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002730A MX2012002730A (es) | 2009-09-04 | 2010-09-03 | Nuevas composiciones y procesos para preparar formulaciones de 1,2,3-triazoles 5-amino o amino sustituidos y triazol orotato. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8377973B2 (es) |
| EP (2) | EP2963023B1 (es) |
| JP (4) | JP2013503861A (es) |
| KR (1) | KR101597338B1 (es) |
| CN (2) | CN102595904B (es) |
| AP (1) | AP3345A (es) |
| AU (1) | AU2010290049B2 (es) |
| BR (1) | BR112012004539A2 (es) |
| CA (1) | CA2772075C (es) |
| CL (1) | CL2012000582A1 (es) |
| HK (1) | HK1212983A1 (es) |
| IL (1) | IL218430A0 (es) |
| MX (2) | MX2012002730A (es) |
| MY (1) | MY159430A (es) |
| NZ (2) | NZ598482A (es) |
| PH (1) | PH12015502088B1 (es) |
| RU (1) | RU2594155C2 (es) |
| SG (1) | SG178413A1 (es) |
| WO (1) | WO2011028288A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8877785B2 (en) * | 2009-09-04 | 2014-11-04 | Tactical Therapeutics Inc | Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate |
| US9089570B2 (en) * | 2010-09-03 | 2015-07-28 | Tactical Therapeutics Inc | Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate |
| US10378059B2 (en) * | 2013-08-02 | 2019-08-13 | Tactical Therapeutics, Inc. | Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate |
| KR102623581B1 (ko) * | 2016-07-18 | 2024-01-11 | 일동제약(주) | 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물 |
| CN112083109B (zh) * | 2019-07-08 | 2021-05-25 | 广东银珠医药科技有限公司 | 羧胺三唑杂质及其制备方法和检测方法 |
| CN112358451B (zh) * | 2021-01-11 | 2021-04-13 | 广东银珠医药科技有限公司 | 羧胺三唑的合成方法 |
| CN113582935A (zh) * | 2021-08-27 | 2021-11-02 | 中国医学科学院放射医学研究所 | 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用 |
| CN113620892B (zh) * | 2021-10-12 | 2022-02-22 | 广东银珠医药科技有限公司 | 羧胺三唑单晶、制备方法及其组合物和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2415740C2 (de) | 1974-04-01 | 1983-12-01 | Servomed Arznei GmbH & Co Pharma KG, 8000 München | Verwendung von Orotsäure bei der analgetischen Behandlung mit Dextropropoxyphen, Natriumsalicylat oder Metamizol |
| US4590201A (en) * | 1984-02-02 | 1986-05-20 | Merck & Co., Inc. | 5-amino or substituted amino 1,2,3-triazoles |
| US4847257A (en) * | 1987-08-20 | 1989-07-11 | Merck & Co., Inc. | 5-Amino or substituted amino 1,2,3,-triazoles useful as antiproliferative agents |
| JPH0356417A (ja) * | 1989-05-08 | 1991-03-12 | Merck & Co Inc | 抗転移剤として有用な５―アミノ又は置換アミノ１，２，３―トリアゾール類 |
| US5359078A (en) * | 1989-05-19 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitor compounds |
| US5132315A (en) * | 1989-05-19 | 1992-07-21 | The United States Of America As Represented By The Department Of Health And Human Services | Therapeutic application of an anti-invasive compound |
| IL122782A (en) * | 1995-07-21 | 2003-03-12 | Gruppe Constantia | Triazole salts and pharmaceutical compositions containing the same and methods for evaluating the susceptibility of a cancer to growth inhibition utilizing the same |
| US5728707A (en) * | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
| TW403740B (en) * | 1997-06-10 | 2000-09-01 | Novartis Ag | Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
| WO2005116024A1 (en) * | 2004-05-25 | 2005-12-08 | Astrazeneca Ab | 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as mao inhibitors for the treatment of bacterial infections |
| US8034823B2 (en) * | 2005-02-22 | 2011-10-11 | Savvipharm Inc | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |
| EP2205596A1 (en) * | 2007-09-24 | 2010-07-14 | Comentis, Inc. | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
| US20150323994A1 (en) * | 2014-05-07 | 2015-11-12 | Immersion Corporation | Dynamic haptic effect modification |
| JP2017150532A (ja) * | 2016-02-23 | 2017-08-31 | Ntn株式会社 | 回転伝達装置 |
-
2010
- 2010-09-03 KR KR1020127008653A patent/KR101597338B1/ko active IP Right Grant
- 2010-09-03 AP AP2012006187A patent/AP3345A/xx active
- 2010-09-03 WO PCT/US2010/002430 patent/WO2011028288A1/en active Application Filing
- 2010-09-03 MX MX2012002730A patent/MX2012002730A/es active IP Right Grant
- 2010-09-03 MY MYPI2012000629A patent/MY159430A/en unknown
- 2010-09-03 JP JP2012527868A patent/JP2013503861A/ja active Pending
- 2010-09-03 CN CN201080050000.2A patent/CN102595904B/zh active Active
- 2010-09-03 BR BR112012004539-3A patent/BR112012004539A2/pt not_active Application Discontinuation
- 2010-09-03 RU RU2012111454/04A patent/RU2594155C2/ru active
- 2010-09-03 CA CA2772075A patent/CA2772075C/en active Active
- 2010-09-03 US US12/807,415 patent/US8377973B2/en active Active
- 2010-09-03 EP EP15178128.3A patent/EP2963023B1/en not_active Not-in-force
- 2010-09-03 NZ NZ598482A patent/NZ598482A/en unknown
- 2010-09-03 AU AU2010290049A patent/AU2010290049B2/en active Active
- 2010-09-03 CN CN201510116934.6A patent/CN104817507A/zh active Pending
- 2010-09-03 SG SG2012010294A patent/SG178413A1/en unknown
- 2010-09-03 EP EP10814093.0A patent/EP2473051B1/en active Active
-
2012
- 2012-03-01 IL IL218430A patent/IL218430A0/en unknown
- 2012-03-02 CL CL2012000582A patent/CL2012000582A1/es unknown
- 2012-03-02 MX MX2014012090A patent/MX355198B/es unknown
-
2013
- 2013-02-27 NZ NZ624636A patent/NZ624636A/en unknown
-
2015
- 2015-09-11 PH PH12015502088A patent/PH12015502088B1/en unknown
- 2015-11-02 JP JP2015215891A patent/JP2016026213A/ja active Pending
-
2016
- 2016-01-29 HK HK16101046.4A patent/HK1212983A1/zh unknown
-
2017
- 2017-08-03 JP JP2017150532A patent/JP2017203038A/ja active Pending
-
2020
- 2020-01-31 JP JP2020014827A patent/JP2020105178A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502088A1 (en) | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | |
| JP7033764B2 (ja) | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 | |
| ES2968809T3 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| CA3118330A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| MY150059A (en) | Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors | |
| WO2009007390A3 (en) | 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors | |
| IL190654A (en) | Methods of Methyl-Sulfonamido-Propanamido, Processes for Preparation and Medicines Containing Them | |
| PL1756086T3 (pl) | Pirydyn-4-ylo-etynylo-imidazole i pirazole jako antagoniści receptora mGlu5 | |
| TN2010000040A1 (en) | 2-3-7-substituted imidazo - [1-2b] pyridazines for treatment of alk 4 or alk 5 mediated diseases | |
| NZ701440A (en) | Pyrazole derivatives as jak inhibitors | |
| IL176547A0 (en) | 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
| WO2006015860A3 (en) | Pyrazole derivatives for treating conditions mediated by activation of the adenosine a2b or a3 receptor | |
| EP3822263A1 (en) | Biaryl ether-type quinazoline derivative | |
| WO2021028806A1 (en) | Heterocyclic wdr5 inhibitors as anti-cancer compounds | |
| IL206514A (en) | History of triazole oxadiazole, their preparation and their pharmaceutical preparations | |
| EA006244B1 (ru) | Производные 2-амино-2-алкил-5-гептеновой и -гептиновой кислот, которые могут быть использованы в качестве ингибиторов синтетазы оксида азота | |
| WO2007013096A8 (en) | Improved process for the preparation of 2r, 3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol (voriconazole) | |
| UA88910C2 (ru) | Гетероциклические соединения для предотвращения или ослабления симптомов заболеваний, которые лечатся коноплей, и способы их получения | |
| UY37222A (es) | PROCEDIMIENTO PARA LA PREPARACIÓN DE DERIVADOS DE 1-FENILO-1,2,4-TRIAZOL SUSTITUIDOS POR 5-HIdroxIalQUILO | |
| WO2010140139A3 (en) | Crystalline forms of 6-(1h- imadazol- 1-yl) -2-phenylquinazoline | |
| CA3159211A1 (en) | Fluorinated quinoline, quinoxaline and benzo[b][1,4]oxazine derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors for the treatment of cancer, autoimmune and inflammatory diseases | |
| UA95780C2 (en) | Xanthine derivatives as selective hm74a agonists | |
| WO2008075163A3 (en) | An improved process for the preparation of rizatriptan | |
| NZ613333A (en) | Derivatives of glyco-cf2-serine and glyco-cf2-threonine | |
| WO2009037244A3 (en) | 5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb1 receptor agonists |